H. Khoury1, Y. Sanaiha1, S. Rudasill1, H. Xing1, A. Mardock1, J. Antonios2, P. Benharash1 1David Geffen School Of Medicine, University Of California At Los Angeles,Cardiothoracic Surgery,Los Angeles, CA, USA 2David Geffen School Of Medicine, University Of California At Los Angeles,Los Angeles, CA, USA
Introduction: Unplanned readmissions are considered a marker for quality of care and are associated with increased resource utilization. The literature on readmissions following alcohol septal ablation (ASA) and septal myectomy (SM) for the treatment of hypertrophic cardiomyopathy remains limited while the impact of center volume on such parameters is poorly characterized.
Methods: The Nationwide Readmissions Database 2010-2015 containing approximately 17 million annual discharges in the U.S., was used to identify all adult (>18 years) patients with the diagnosis of hypertrophic cardiomyopathy. Diagnosis and procedural codes were used to identify patients undergoing ASA and SM, respectively. Hospitals were characterized based on annual ASA/SM case volume into low (LVH), medium (MVH), and high (HVH) volume tertiles. Student t-tests and chi-squared tests were used to analyze baseline continuous and categorical variables, respectively. The independent impact of hospital volume on mortality and readmission was determined using multivariable logistic regression.
Results: Of 7,957 patients who underwent septal reduction procedures, 4,870 (61.2%) underwent alcohol septal ablation and 2,727 (38.8%) underwent septal myectomy. Patients who underwent ASA at a LVH experienced higher rates of readmission (12.6 vs. 10.0 vs. 7.0%, P<0.001), emergent index admission (50.2 vs. 30.8 vs. 43.4%, P<0.001), overall in-hospital complications (28.1 vs. 24.5 vs. 20.6%, P=0.012), and comorbid atrial fibrillation (51.2 vs. 37.9 vs. 43.2%, P=0.005), and renal failure (12.9 vs. 11.6 vs. 8.2%, P=0.030) than those at MVH and HVH. Additionally, length of stay (5.2 vs. 4.4 vs. 4.2 days, P=0.033) and index ASA costs ($28,022 vs. $25,089 vs. $23,792, P=0.039) were greater in LVH. In contrast, patients who underwent SM at a LVH experienced lower rates of in-hospital complications (37.8 vs. 34.1 vs. 45.6%, P=0.049), and comorbid coagulopathy (8.5 vs. 19.0 vs. 23.5%, P<0.001) than patients who underwent SM at a HVH. For both procedures, rates of in-hospital mortality were not significantly different between hospital tertiles. While hospital SM volume was not identified as an independent predictor for thirty-day readmission, ASA performed LVH (adjusted OR, 1.96; 95% CI 1.20–3.21) or MVH (adjusted OR, 1.55; 95% CI 1.02–2.35) was an independent predictor for emergent thirty-day readmission, compared to HVH (Figure).
Conclusion: Low and medium hospital volume were found to be associated with increased and thirty-day readmission following ASA, but not SM. Patients with hypertrophic cardiomyopathy should be referred to experienced centers for ASA to reduce rates of readmissions and decrease national healthcare expenditures.